Heart rate dynamics at the onset of ventricular tachyarrhythmias as retrieved from implantable cardioverter-defibrillators in patients with coronary artery disease

What is the adequate sampling interval of the ECG signal for heart rate variability analysis in the time domain?

Heart rate variability (HRV) analysis is considered a simple method for investigating neurocardiac regulation. However, measures of HRV may be corrupted by technical artifacts. In order to investigate the consequences of digitization errors on the time domain parameters, HRV measures from model tachograms resampled at different rates were compared. Two 375-element tachograms from human ECG tracings were shifted to a mean of 800 ms and stretched to standard deviations (SD) of 5-120 ms in 5 ms steps. All were resampled at 1-10 ms in 1 ms steps, 10 times repetitively at each interval. The mean, SD, relative accuracy error (RAE) and relative precision error (RPE) were calculated from the mean RR-interval, SD (SDNN), root mean square of successive RR-differences (RMSSD) and the percentage of consecutive RR-interval differences greater than 50 ms (pNN50). The RAE and RPE of the mean heart rate were below 0.1%. In the series with 5 ms SD, the SDNN-RAE exceeded 30% at 10 ms SI, its RPE was lower than 2% all through. Resampling the 15 ms SD tachogram at 1, 2, 4, or 10 ms resulted in RMSSD-RAE of 0.7%, 2.5%, 7.8% and 45.1%, respectively, while its RPE remained below 5%. The pNN50 shows poor accuracy and precision. An ECG sampling interval of 1 ms is recommended for HRV analysis without interpolation in order to get accurate time domain measures even in seriously reduced-variability samples. However, a lower sampling rate may be satisfactory in cases where higher variability is expected.

Factors affecting diurnal variability of ventricular tachyarrhythmias detected by multiprogrammable implantable cardioverter-defibrillators

Many cardiovascular events, including ventricular arrhythmias, display diurnal variability with a morning peak, and a less pronounced afternoon peak. Since the advent of multiprogrammable implantable cardioverter-defibrillators (ICDs), it has been possible to analyse ventricular tachyarrhythmic events. This study aims to evaluate the circadian pattern of ventricular tachycardias in patients treated with ICDs and examines whether antiarrhythmic medications affect this pattern. Data recorded from 83 patients' ICDs were manually analysed and events other than ventricular arrhythmias were excluded. There was a morning peak of ventricular arrhythmias at around 9.00 a.m. This peak was maintained in patients with ejection fractions of less than 40% and those whose arrhythmias had cycle lengths of less than 230ms. Beta blockers appeared to have no effect on this morning peak but the peak appeared later with amiodarone.

Heart rate variability before ventricular arrhythmias in patients with coronary artery disease and an implantable cardioverter defibrillator

BACKGROUND

Changes in autonomic regulation of the heart may be responsible for the occurrence of arrhythmias. Although a decrease in 24-hour heart rate variability is a strong predictor of subsequent arrhythmias in patients with heart disease, many questions remain unanswered concerning changes in heart rate and heart rate variability in the minutes or hours preceding an arrhythmia. The aim of our study was to analyze changes in heart rate and heart rate variability occurring during the 90 minutes preceding an arrhythmia, in patients with coronary heart disease and an implantable defibrillator.

MATERIALS AND METHODS

Thirty-eight patients, with a total of 93 episodes of ventricular arrhythmia, were included in the study. Heart rate and heart rate variability were measured in three 30-minute and five 2-minute periods preceding the arrhythmia. Heart rate variability was assessed using measurements of Poincaré plots.

RESULTS

The results show a gradual increase in heart rate before the arrhythmia, from 73+/-13/min, to 75+/-14/min, and finally 78+/-15/min in the 90 minutes preceding the arrhythmia (P<0.05).

CONCLUSION

Measurements of Poincaré plots showed a significant increase in their length and no significant change in their width. These results suggest that sympathetic activation is the predominant change in autonomic nervous system before a ventricular arrhythmia in patients with coronary heart disease. This change may occur as early as one hour and a half before the arrhythmia.

Effect of elevated heart rate preceding the onset of ventricular tachycardia on antitachycardia pacing effectiveness in patients with implantable cardioverter defibrillators

The incorporation of antitachycardia pacing (ATP) into implantable cardioverter defibrillators (ICDs) has provided a better tolerated alternative to shocks. ATP has been shown to be effective in terminating approximately 80% to 90% of spontaneous ventricular tachycardia (VT) episodes. Although ATP is routinely used, little is known about predictors of ATP failure. Based on the evaluation of stored electrograms, we aimed to prospectively follow patients with ICDs, and to analyze parameters affecting ATP effectiveness. One hundred eighteen consecutive patients received ICDs for standard indications. Before discharge, empirical, standardized ATP therapy was programmed in all patients within VT zones. A total of 1,218 spontaneous tachycardia episodes occurred in 51 patients during a mean follow-up of 24.5 +/- 12 months. Among these, 888 VTs were diagnosed. One hundred four fast VTs were detected in the ventricular fibrillation zone and treated with primary shock delivery. ATP was attempted 881 times in the remaining 784 VT episodes. ATP terminated 640 VTs successfully, ATP failed in 55 VTs finally reverted by shocks, and 89 VTs converted to a slower VT outside the VT zone. Fifty-one of these slower VTs reverted spontaneously, and 38 were redetected and treated. Finally, in primary intention-to-treat basis, ATP was successful in 691 VTs (88%) and unsuccessful in 93 VTs (12%). There was no influence of VT cycle length on ATP success rate. Furthermore, ATP efficacy was similar between patients with left ventricular ejection fraction < or =35% or >35%, between daytime and nighttime, as well as between patients with ischemic or nonischemic cardiomyopathy. A faster heart rate immediately preceding the onset of VT (103 +/- 19 vs 78 +/- 14 beats/min, respectively, hazard ratio 4.08, 95% confidence interval 2.11 to 7.89, p <0.001), and absence of beta-blocker therapy (82% vs 93%, respectively, hazard ratio 2.71, 95% confidence interval 1.72 to 4.29, p = 0.02) were found, by Cox proportional-hazard analysis, to be the sole independent predictors of ATP ineffectiveness in ICD recipients. Thus, the present study identified both preceding sinus tachycardia (reflecting an increased sympathetic tone) and lack of beta-blocker use as independent risk factors for reduced success of ATP therapy in terminating VT. Therefore, modification of sympathetic tone may be beneficial for patients with ICDs.

Study of precursors of ventricular tachycardia from data stored in the memory of a dual chamber implantable cardioverter defibrillator

This study was performed to examine precursors of ventricular tachyarrhythmias in patients who experienced a sustained ventricular tachyarrhythmia and received appropriate therapy by ICD. From an overall consecutive population of 77 patients, 18 patients (1 woman, mean age 61.7 +/- 10.8 years) were selected for having experienced a sustained ventricular tachyarrhythmia and received at least one appropriate ICD therapy preceded by 20 minutes of internal information. The number of premature ventricular complexes (PVCs)/min for each of the 20 minutes preceding the onset of ventricular tachyarrhythmia, the shortest coupling intervals between PVC and normal sinus beat, and the presence of short-long-short (SLS) interval sequences were examined. Data were stratified according to underlying disease, left ventricular ejection fraction, rate of ventricular tachyarrhythmia, and antiarrhythmic therapy. One hundred twenty-eight episodes of spontaneous ventricular tachyarrhythmia were retrieved. Rapid ventricular tachyarrhythmia (>160 beats/min) were preceded by a significantly greater mean number (3.71 +/- 6.36)of PVCs than slower ventricular tachyarrhythmia (<or=160 beats/min) (0.63 +/- 0.88, P = 0.0004). The mean shortest PVC coupling interval was significantly shorter in patients with (588 +/- 99 ms) versus without (643 +/- 111 ms, P = 0.03)ischemic heart disease, before episodes of rapid(527 +/- 55 ms)versus slower (636 +/- 105 ms, P = 0.0001)ventricular tachyarrhythmia, and in the absence (538 +/- 80 ms)versus the presence(620 +/- 105 ms, P = 0.006)of amiodarone. SLS sequences preceded 29% of rapid ventricular tachyarrhythmic episodes, versus 8% of the slower ventricular tachyarrhythmia (P < 0.01). Significant differences were found in the characteristics of PVCs preceding ventricular tachyarrhythmic episodes in accordance to their rate and the underlying cardiomyopathy. Though insufficient in isolation, these findings may be helpful when combined with other observations to develop preventive algorithms, or to refine the programming of implantable devices.

Circadian heart rate and blood pressure variability considered for research and patient care

OBJECTIVES

To review mechanisms of circadian variations in heart rate variability (HRV) and blood pressure variability (BPV) and mortality and morbidity due to cardiovascular diseases (CVD).

METHODS

Results from 7-day/24-h HRV and BPV are interpreted by gender and age-specified reference values in the context of a Medline search.

RESULTS

Abnormal HRV and BPV measured around the clock for 7 days provides information on the risk of subsequent morbid events in subjects without obvious heart disease and without abnormality outside the conventional (in the sense of chronobiologically unquantified) physiological range. Meditation, beta-blockers, ACE inhibitors, n-3 fatty acids and estrogens may have a beneficial influence on HRV, but there is no definitive outcome-validated therapy. Low HRV has been associated with a risk of arrhythmias and arrhythmic death, unstable angina, myocardial infarction, progression of heart failure and atherosclerosis. BPV may be characterized by treatable circadian-hyper-amplitude-tension (CHAT), which can be transient '24-h CHAT' or '7-day-CHAT', MESOR-hypertension and/or an unusually-timed (odd) circadian acrophase (ecphasia), all associated with an increased risk of stroke, stroke death, myocardial infarction, and kidney disease.

CONCLUSIONS

Precise insight into the patho-physiology in time of HRV and BPV is needed with development of a consensus on best measures of HRV for clinical purposes and to determine when a 7-day record interpreted chronobiologically suffices and when it does not, for detection within as well as outside the conventional normal range, for diagnostic clinical practice and to direct therapy of risk greater than that associated with hypertension, smoking or any other risk factor.

Heart rate variability analysis

The expansion of heart rate variability analysis has been facilitated by the remarkable development of computer sciences and digital signal processing during the last thirty years. The beat-to-beat fluctuation of the heart rate originates from the momentary summing of sympathetic and parasympathetic influences on the sinus node. According to the extensive associations of the autonomic nervous system, several factors affect heart rate and its variability such as posture, respiration frequency, age, gender, physical or mental load, pain, numerous disease conditions, and different drugs. Heart rate variability can be quantitatively measured by time domain and frequency domain methods that are detailed in the paper. Non-linear methods have not spread in the clinical practice yet. Various cardiovascular and other pathologies as well as different forms of mental and physical load are associated with altered heart rate variability offering the possibility of predicting disease outcome and assessing stress.

Heart rate variability before the onset of ventricular tachycardia: differences between slow and fast arrhythmias

BACKGROUND

We tested whether or not heart rate variability (HRV) changes can serve as early signs of ventricular tachycardia (VT) and predict slow and fast VT in patients with an implantable cardioverter defibrillator (ICD).

METHODS AND RESULTS

We studied the ICD stored 1000 beat-to-beat intervals before the onset of VT (131 episodes) and during a control time without VT (74 series) in 63 chronic heart failure ICD patients. Standard HRV parameters as well as two nonlinear parameters, namely 'Polvar10' from symbolic dynamics and the finite time growth rates 'Fitgra9' were calculated. Comparing the control and the VT series, no linear HRV parameter showed a significant difference. The nonlinear parameters detected a significant increase in short phases with low variability before the onset of VT (for time series with less than 10% ectopy, P<0.05). Subdividing VT into fast (cycle length <or=270 ms) and slow (>270 ms) events, we found that the onset of slow VT was characterized by a significant increase in heart rate, whereas fast VT was triggered during decreased heart rates, compared to the control series.

CONCLUSIONS

Our data may permit the development of automatic ICD algorithms based on nonlinear dynamic HRV parameters to predict VT before it starts. Furthermore, they may facilitate improved prevention strategies.

Can nutrition influence circadian rhythm and heart rate variability?

Recent studies indicate that there is an interaction between biorhythms, the biological clock and triggers, which may be important in the pathogenesis of altered heart rate variability (HRV) and blood pressure variability (BPV). Circadian rhythms are under the influence of, and physiological variables are mediated by the activation of the adrenals, sympathetic/parasympathetic, hypothalamic and pituitary activity. Emotional stress, physical exertion, sleep deprivation and large fatty meals are major triggers of myocardial ischemia, angina, infarction, sudden cardiac death (SCD) and stroke. These events have been reported to exhibit a circadian variation with increased frequency in the second quarter of the day, which has also been observed in our studies on Indians. Recent studies indicate that altered HRV and BPV are also important in the pathogenesis and progression of heart failure, atheroma and thrombosis. Mediation via beta-blockers, oestrogens, n-3 fatty acids, vitamin E and coenzyme Q10 and fasting appears to have a beneficial influence whereas progestins, nifedipine, stress and exercise may have an adverse effect on HRV and BPV. We have reported that plasma levels of vitamin E and C are lower in the second quarter of the day than at other times, indicating their role in the pathogenesis of variability and cardiac events. Prospective studies also indicate that HRV and BPV are important and independent risk factors for cardiovascular events. However, no study has yet been conducted in patients with abnormal HRV and BPV in a randomized, placebo-controlled intervention trial to find out whether improvement in variability can cause a significant reduction in cardiovascular events. There is a need to study the role of n-3 fatty acids, coenzyme Q10, the effect of regular physical training, medication and ACE inhibitors in patients with abnormal HRV and BPV to demonstrate that improving variability can modulate cardiovascular events.

Heart rate variability and cardiovascular mortality

The autonomic nervous system plays a major role in affecting the cardiac milieu and promoting malignant ventricular activity. The measurement of heart rate variability (HRV) is a noninvasive tool for assessing the status of the autonomic nervous system. A depressed HRV among post-myocardial infarction patients is a well-established risk factor for arrhythmic death. A reduced HRV has also been used to identify diabetic patients with autonomic neuropathy. This paper presents recent developments in the use of HRV, focusing on further refinement and validation of the use of both linear and nonlinear dynamics for sudden death prognostication, evaluation of the effect of specific pharmacologic agents on HRV, and assessment of HRV in health and in specific disease states that have been associated with an increased mortality risk.

Cardiogenic shock and cardiac arrest

Severe heart disease may cause hypotension and hypoperfusion, and ultimately circulation may cease altogether. These two clinical syndromes are cardiogenic shock and cardiac arrest, respectively. This review summarizes the causes and clinical features of each, and describes the treatment options available to clinicians managing patients in cardiogenic shock.

The beta blockers: are they as protective in hypertension as in other cardiovascular conditions?

Beta blockers are frequently used to treat hypertension because of their well established safety and efficacy. Large clinical trials yield a 12%--20% decline in cardiovascular end points in hypertensive patients treated with beta blockers. However, beta blockers account for only 11% of antihypertensive prescriptions, and their use appears to be declining as newer agents with fewer side effects become available. The metabolic side effects of beta blockers have recently been examined. While they may raise triglycerides, lower high-density lipoprotein cholesterol, induce glucose intolerance, and possibly unmask diabetes, these effects have not been shown to impact their clinical effectiveness. For hypertension, beta blockers are still recommended as first-line therapy in many patients, particularly those at high risk for cardiovascular disease. They are also indicated for other cardiovascular disorders, such as congestive heart failure and postmyocardial infarction, in which mortality reductions exceed that seen with hypertension treatment in patients without cardiovascular complications. (c)2001 Le Jacq Communications, Inc.